Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 1)
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus
Sponsor: AstraZeneca
A PHASE3 clinical study on Type 1 Diabetes Mellitus, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 12 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Apr 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aguascalientes, Mexico , Albany, United States , Almería, Spain , Amarillo, United States , Arhus C, Denmark , Aschaffenburg, Germany , Asheville, United States , Aurora, United States , Aßlar, Germany and 117 more locations